Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 12/2017

01-12-2017 | Review article

Biomarkers in pancreatic ductal adenocarcinoma

Authors: J. Gallego, C. López, R. Pazo-Cid, F. López-Ríos, A. Carrato

Published in: Clinical and Translational Oncology | Issue 12/2017

Login to get access

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is currently the third most frequent form of malignancy. The role of biomarkers in the diagnostic and therapeutic strategy of cancer is constantly expanding. Translational research is already changing paradigms in tumours encompassing from early diagnosis to precision medicine in advanced disease. Nomenclature for molecular subtypes of tumours is gradually gaining acceptance and there are growing expectations it will further go from the bench to the bedside. However, the clinical relevance of biomarkers in PDAC is still far behind the relevance of biomarkers in other solid tumours. This article is part of a wider project (GALLgo) involving over forty specialists devoted to the multidisciplinary management of PDAC which concluded in recommendations based on scientific evidence. The aim of the present article is to review the diagnostic, prognostic and predictive biomarkers, either in localised or advanced disease, which have been lately subjected to study and analysis and others currently available for PDAC in order to give strength-graded recommendations linked to quality of evidence that can be used as guidelines in routine clinical practice.
Literature
1.
GLOBOCAN. European age-standardised rates calculated by the statistical information team at cancer research UK, 2011 using data from GLOBOCAN 2008 v1.2, IARC, version 1.2. http://​globocan.​iarc.​fr. Accessed Feb 2016.
2.
Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33:139–44.CrossRefPubMed
3.
Matulonis UA, Penson RT, Domchek SM, Kaufman B, Shapira-Frommer R, Audeh MW, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33:244–50.
4.
Holter S, Borgida A, Dodd A, Grant R, Semotiuk K, Hedley D, et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol. 2015;33:3124–9.CrossRefPubMed
5.
Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KD, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495–501.CrossRefPubMedPubMedCentral
6.
Yeo TP. Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma. Semin Oncol. 2015;42:8–18.CrossRefPubMed
7.
Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;S5:v56–68.
8.
Yi JM, Guzzetta AA, Bailey VJ, Downing SR, Van Neste L, Chiappinelli KB, et al. Novel methylation biomarker panel for the early detection of pancreatic cancer. Clin Cancer Res. 2013;19:6544–55.CrossRefPubMedPubMedCentral
9.
Ferrone CR, Kattan MW, Tomlinson JS, Thayer SP, Brennan MF, Warshaw AL, et al. Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival. J Clin Oncol. 2005;23:7529–35.CrossRefPubMedPubMedCentral
10.
Uzunoglu FG, Reeh M, Vetorazzi E, Ruschke T, Hannah P, Nentwich MF, et al. Preoperative Pancreatic Resection (PREPARE) score. A prospective multicenter-based morbidity risk score. Ann Surg. 2014;260:857–64.CrossRefPubMed
11.
Humphris JL, Chang DK, Johns AL, Scarlett CJ, Paijic M, Jones MD, et al. Prognostic and predictive value of serum CA 19.9 in pancreatic cancer. Ann Oncol. 2012;23:1713–22.CrossRefPubMedPubMedCentral
12.
Yang JJ, Hu CG, Shi WX, Denq T, He SQ, Yuan SG, et al. Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysis. World J Gastroeterol. 2015;21:2807–15.CrossRef
13.
Bachet JB, Maréchal R, Demetter P, Bonnetain F, Couvelard A, Syrcek M, et al. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Ann Oncol. 2012;23:2327–35.CrossRefPubMed
14.
Kim H, Park CY, Lee JH, Cho CK, Kim KH. Ki-67 and p53 expression as a predictive marker for early postoperative recurrence in pancreatic head cancer. Ann Surg Treat Res. 2013;88:200–7.CrossRef
15.
Xie H, Jiang W, Xiao SY, Liu X. High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma. J Histochem Cytochem. 2013;61:148–55.CrossRefPubMedPubMedCentral
16.
Maréchal R, Bachet JB, Calomme A, Demetter P, Delpero JR, Syrcek M, et al. Sonic hedgehog and Gli1 expression predict outcome in resected pancreatic adenocarcinoma. Clin Cancer Res. 2015;21:1215–24.CrossRefPubMed
17.
Stratford JK, Bentrem DJ, Anderson JM, Fan C, Volmar KA, Marron JS, et al. A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med. 2010;7:e1000307.CrossRefPubMedPubMedCentral
18.
Hamada T, Nakai Y, Yasunaga H, Isayama H, Matsui H, Takahara N, et al. Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. Br J Cancer. 2014;110:1943–9.CrossRefPubMedPubMedCentral
19.
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–6.CrossRefPubMed
20.
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.CrossRef
21.
Tabernero J, Chiorean G, Infante JR, Hingorani SR, Ganjue V, Weeks C, et al. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Oncologist. 2015;20:1–8.CrossRef
22.
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouam Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRefPubMed
23.
Bauer TM, El-Rayes BF, Li X, Hammad N, Philip PA, Shields AF, et al. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials. Cancer. 2013;119:285–92.CrossRefPubMed
24.
Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015;107:1–10.
25.
Qi Q, Geng Y, Sun M, Wang P, Chen Z. Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer. Pancreatology. 2015;15:145–50.CrossRefPubMed
26.
27.
Capello M, Lee M, Wang H, Babel I, Katz MH, Fleming JB, et al. Carboxylesterase 2 as a determinant of response to irinotecan and neoadjuvant FOLFIRINOX therapy in pancreatic ductal adenocarcinoma. J Natl Cancer Inst. 2015;107:1–9.CrossRef
28.
Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S, Maitra A, et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther. 2011;10:3–8.CrossRefPubMed
29.
Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17:500–3.CrossRefPubMedPubMedCentral
30.
Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47:1168–78.CrossRefPubMedPubMedCentral
31.
Combs SE, Habermehl D, Kessel KA, Bergmann F, Werner J, Naumann P, et al. Prognostic impact of CA 19.9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer. Ann Surg Oncol. 2014;21:2801–7.CrossRefPubMed
32.
Lee JW, Kang CM, Choi HJ, Lee WJ, Song SY, Lee H, et al. Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative 18F-FDG PET/CT in patients with pancreatic cancer. J Nucl Med. 2014;55:898–904.CrossRefPubMed
33.
Haas M, Heinemann V, Kullmann F, Laubender RP, Klose C, Bruns CJ, et al. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol. 2013;139:681–9.CrossRefPubMed
34.
Aranda E, Manzano JL, Rivera F, Galán M, Valladares-Ayerbes M, Pericay C, et al. Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study). Ann Oncol. 2012;23:1919–25.CrossRefPubMed
35.
Ramanathan RK, Von Hoff DD, Moore MJ, Texeira L, Salvatore S, Tabernero J, et al. Analysis of metabolic response by positron emission tomography compared with tumor response by computed tomography from MPACT, a phase III trial comparing nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. J Clin Oncol. 2014;32:254 (abstr).CrossRef
Metadata
Title
Biomarkers in pancreatic ductal adenocarcinoma
Authors
J. Gallego
C. López
R. Pazo-Cid
F. López-Ríos
A. Carrato
Publication date
01-12-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 12/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1691-5

Other articles of this Issue 12/2017

Clinical and Translational Oncology 12/2017 Go to the issue

Review article

Pancreatic ductal adenocarcinoma: metastatic disease

Research Article

Haemoglobin monitoring in endometrial cancer patients undergoing radiotherapy

Research Article

Influence of ovarian cancer type I and type II microenvironment on the phenotype and function of monocyte-derived dendritic cells

Research Article

Overexpression of dishevelled 2 is involved in tumor metastasis and is associated with poor prognosis in hepatocellular carcinoma

Research Article

Annual hazard rate of relapse of stage II and III colorectal cancer after primary therapy

Review Article

SLC14A1: a novel target for human urothelial cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits